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Available online 31 October 2013AbstractAccurate identification of the cause of chest pain is a challenge to the emergency physician because a significant proportion of patients with
acute coronary syndrome (ACS) present atypically. Cardiac troponins are the most sensitive and specific biochemical markers of myocardial
damage, and are an important diagnostic tool in the evaluation of ACS. High-sensitivity troponins (hsTn) have been introduced in recent years,
and have been shown to have increased accuracy in the diagnosis of acute myocardial infarction (AMI), both at presentation and upon early onset
of chest pain. A combination of hsTn readings at presentation and at either 2 hours or 3 hours after the onset of symptoms increases the
sensitivity of diagnosing AMI as compared to at presentation alone, and this combination may negate the need for other cardiac markers. The
absolute change in hsTn 2 hours after presentation was also found to be useful in the diagnosis of AMI, but not the relative change. However,
hsTn has lower specificity in comparison with traditional troponin, and its levels may be elevated even in certain non-ACS settings. The
interpretation of troponin values in patients with chronic renal failure must also be done with caution, as their baseline may be elevated, even in
the absence of an acute event. Given these pitfalls, the assessment of ACS must still be global, comprising clinical history, electrocardiogram
changes, troponin increase, and/or a new wall-motion abnormality on echocardiogram or nuclear scan showing new loss of viable myocardium.
High-sensitivity troponin also has a potential use in prognosticating atherosclerotic disease in chronic renal patients as well as population
screening of cardiovascular risk factors, although these uses have not been well studied. Identification of patients with unstable angina without
myocardial infarction also remains a challenge, as the sensitivity of cardiac troponin in this area remains moderate to low. However, new cardiac
markers such as copeptin, ischemia-modified albumin, and heart-type acid binding protein, are still being studied and provide a window of hope
in the diagnosis of unstable angina.
Copyright  2013, Taiwan Society of Emergency Medicine. Published by Elsevier Taiwan LLC. All rights reserved.
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Accurate identification of the cause of chest pain is a
challenge to the emergency physician because a significant
proportion of patients with acute coronary syndrome (ACS)
present atypically.1 The single or serial 12-lead electrocar-
diogram (ECG) performed at the emergency department (ED)
has a sensitivity of only 40e60% for acute myocardial* Corresponding author. Department of Emergency Medicine, Singapore
General Hospital, Outram Road, Singapore 169608.
E-mail address: lim.swee.han@sgh.com.sg (S.H. Lim).
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http://dx.doi.org/10.1016/j.jacme.2013.08.001infarction (AMI) or ACS.2 ST segment elevations, which are
classically seen in the setting of a transmural myocardial
infarction, can also be observed in non-ACS conditions such
as acute pericarditis, left ventricular hypertrophy, left bundle
branch block, Brugada syndrome, and early repolarization
patterns.2. Use of cardiac markers in the diagnosis of ACS
In the past 30 years, improved immunochemical techniques
have made it possible for rapid measurements of a variety of
markers indicating myocardial cell death. Several of theseMedicine. Published by Elsevier Taiwan LLC. All rights reserved.
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muscleebrain type (CK-MB), and troponins, have been found
to be more sensitive in detecting AMI than based on history
and ECG alone.3e5
Myoglobin is a low molecular weight protein (17 kD) found
in muscle tissue. In myocardial injury, myoglobin rises in the
initial 1e3 hours, then peaks at 5e7 hours, and returns to
baseline by 24 hours. In theory, it is attractive as an early
indicator of myocardial injury; however, myocardial myoglo-
bins are not currently distinguishable immunologically from
skeletal muscle myoglobin. As such, myoglobin levels may be
elevated in patients with renal failure because of reduced
clearance. It is also elevated in any clinical situation involving
the skeletal muscle, such as trauma, significant systemic
illness, or even strenuous exercise. Hence, it should be sup-
plemented by a more cardiac specific-marker such as CK-MB
or cardiac troponin.6
Due to the lack of a better marker, CK-MB was held as gold
standard for AMI diagnosis in the late 1980s and 1990s. It is
found in serum 3e8 hours after myocardial cell death with
levels peaking at 10e24 hours and normalized within 2e3
days. Previous studies have demonstrated that diagnosis of
AMI can be effectively established through the detection of
rising levels of CK-MB within 6 hours after onset of symp-
toms.4 Unfortunately, both false positives and false negatives
have also been reported.
In the myocardium, both CK-MB and muscleemuscle type
CK are present. Even though muscleemuscle type is the pre-
dominant type of CK-isoenzyme, skeletal muscle does contain
small amounts of CK-MB (1e3%). Abnormal CK-MB eleva-
tion may be seen in trauma, muscular dystrophies, myositis,
rhabdomyolysis, and after extremely vigorous exercise.
Later studies have shown that among chest pain patients,
elevated conventional cardiac troponin (cTn) is a better pre-
dictor of 1-month and 1-year adverse cardiac events. Acute
coronary syndrome patients who have normal troponin value
and elevated CK-MB have excellent outcomes. However,
patients who have elevated cTn levels without an elevated CK-
MB have increased risk for developing future events.7 More-
over, acute coronary syndrome patients with CK-MB negative
but with a positive cTn result showed a benefit with aggressive
antiplatelet and anticoagulation treatment, whereas patients
with both negative CK-MB and cTn did not.8,9
Currently, two types of cTndmyocardial troponin T
(TnT)5 and troponin I (TnI)10dare used as markers of ACS.
These troponins are genetically distinct from troponin forms
found in other muscle tissue, and monoclonal antibodies to
these troponins have little cross-reactivity with troponins from
skeletal muscles. Unlike CK-MB, cTn is not found in serum of
healthy individuals as there is very little day-to-day turnover
of cardiac myocytes.
Normally, small quantities of troponins are found free in
the myocardial cytosol. The majority is entwined in cardiac
myofibrils. After myocardial injury, there is a biphasic rise in
serum troponins. The initial surge corresponds to an early
release of the free cytoplasmic proteins. This is then followed
by a delayed and greatly prolonged rise consistent withbreakdown of the cardiac muscle fiber over the next 5e7 days.
This persistence is an advantage over CK-MB in patients who
present late.
The sensitivity of cTn in detecting an AMI is low within
the first hours after onset of chest pain, with a sensitivity of
approximately 50% within 3e4 hours of an event. At about 6
hours after the onset of symptoms, the test is positive in about
75% of AMI patients, and in almost 100% at about 12 hours
postevent.11 Serial measurements of cardiac markers have
been noted to improve the sensitivity of this instrument in
diagnosis of AMI. Troponins are more sensitive for the
diagnosis of myocardial injury than CK-MB with the po-
tential of a less likelihood for inadvertently discharging pa-
tients with acute coronary syndrome from the ED. CK-MB
might no longer required for the evaluation of ACS
patients.12
3. Beginning of cardiac troponins
Since 2000, cTn has taken center stage for the diagnosis of
AMI. ACC/ESC recommended the use of cTn level, equiva-
lent to the 99th percentile of a reference population, measured
with imprecision ( 10% coefficient of variation, CV), as the
cut-off value for the diagnosis of cardiac injury.13 Until
recently, 10% of CV values of the various troponin assays
were always higher than the 99th percentile value, and were
thus commonly used as the cut-off value instead of the 99th
percentile value.
To date, only one manufacturer produces TnT assays
(Roche Elecsys, Roche Diagnostics, Basel, Switzerland), and
its 99th percentile cut-offs and 10% CV are well established.
There are more than 10 commercially available TnI assays,
each with their own 99th percentile and 10% CV levels.14
4. High-sensitivity troponins
A new generation of high sensitive assays for cardiac tro-
ponins (I and T) has been introduced, with the 99th percentile
value of high-sensitivity troponin (hsTn) lower than the 10%
CV. Two landmark studies on hsTn in the diagnosis of AMI
have been published.15,16
The Advantageous Predictors of Acute Coronary Syndrome
Evaluation (APACE) is a prospective study that enrolled 786
consecutive patients presenting to the ED with chest pain
suggestive of ACS or angina equivalent, in which the onset or
peak of symptoms had occurred within 12 hours of presenta-
tion.15 Patients with end stage renal failure on dialysis were
excluded. Blood was drawn at presentation, 1 hour, 2 hours, 3
hours, and 6 hours after presentation. The study end points
were a final diagnosis of AMI or unstable angina within 60
days follow-up. The diagnosis of unstable angina required a
positive cardiac exercise test or cardiac angiogram showing
stenosis of >70% of one or more coronary arteries. The final
diagnosis was adjudicated by two independent cardiologists
reviewing all available records.
A summary of the results is shown in Tables 1 and 2.
Seventeen percent of patients had a final diagnosis of AMI,
Table 2
Comparison between high-sensitivity troponins (hsTn) versus conventional
troponin T (cTnT) in patients with recent chest pain (within 3 hours of onset)
in the diagnosis of acute myocardial infarction.
Troponin Area under the curve
(95% CI)
A p-value of comparison
of sensitivity with cTnT
AbbotteArchitect TnI 0.96 (0.88e0.99) 0.010
Roche hsTnT 0.92 (0.87e0.97) 0.010
Roche troponin I 0.92 (0.86e0.99) 0.020
Siemens TnI ultra 0.94 (0.90e0.98) 0.005
cTnT 0.76 (0.64e0.88) N/A
CI ¼ confidence interval.
Note. Data from “Early diagnosis of myocardial infarction with sensitive
cardiac troponin assays” by T. Reichlin, W. Hochholzer, S. Bassetti, et al.
2009, N Engl J Med. 361, p. 858e67.
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diagnostic accuracy for AMI was significantly higher with the
four sensitive troponin assays (Abbott-Architect TnI [Abbott
Diagnostics, Abbott Park, IL, USA], Roche high sensitive
troponin T [Roche Diagnostics, Basel, Switzerland], Roche
TnI [Roche Diagnostics], Siemens TnI ultra [Siemens
Healthcare Diagnostics, Erlangen, Germany]) than with the
cTn assays (Roche Troponin T, Roche Diagnostics) at the time
of presentation (Table 1). In this article, units for troponin
levels are standardized as pg/mL instead of the conventional
ng/mL due to the relatively smaller values of hsTn.
The superiority of hsTn over cTnT in the diagnosis of AMI
is more profound in patients presenting to ED within 3 hours
of onset of chest pain (Table 2).
However, the area under the curve (AUC) for diagnosis of
unstable angina is low to moderate, with substantial difference
among the assays: AbbotteArchitect TnI, 0.56; 95% confi-
dence interval (CI), 0.59e0.71; for Roche hsTnT, 0.76; 95%
CI, 0.71e0.81; for Roche TnI, 0.56; 95% CI, 0.50e0.63; and
for Siemens TnI, 0.68; 95% CI, 0.62e0.74.
A follow-up study from APACE showed that early (after
both 1 hour and 2 hours) absolute hsTnI (Siemens TnI ultra) or
hsTnT Roche changes were superior to relative hsTn changes
in diagnosing AMI.17 The receiver operating characteristic
(ROC) curve-derived optimal cut-off values for absolute
changes within 2 hours corresponded to approximately half of
the 99th percentile value (7 pg/mL for hsTnT and 20 pg/mL for
hsTnI). The superiority of absolute over relative change of
hsTn levels was independent of underlying baseline hsTn
values and time of onset of symptoms, and was also found to
be applicable to the elderly and patients with impaired renal
function. A combination of baseline hsTn levels with 1-hour or
2-hour absolute changes, but not relative changes, significantly
improved the diagnostic accuracy of AMI as compared to
when only baseline hsTn levels were used. Diagnostic accu-
racies for AMI provided by early absolute changes within 1
hour or 2 hours were not inferior compared with changes
within 6 hours. However, this finding might be confounded by
the fact that patients with AMI had elevated 0-hour, 1-hour, or
2-hour hsTn and were often already transferred to the coronary
catheterization laboratory or coronary care units by 6 hours.
Only 36% of the study populations had values of hsTn at
baseline as well as after 1 hour, 2 hours, and 6 hours. Further
confirmatory studies should to be done to determine whetherTable 1
Comparison between high-sensitivity troponins (hsTn) versus conventional troponin
Troponin Area under the curve (95% CI) LoD, pg/mL
AbbotteArchitect TnI 0.96 (0.94e0.98) 10
Roche hsTnT 0.94 (0.94e0.98) 3
Roche TnI 0.94 (0.92e0.97) 100
Siemens TnI ultra 0.96 (0.94e0.98) 6
cTnTa 0.90 (0.86e0.94) 33
CI ¼ confidence interval; CV ¼ coefficient of variance; LoD ¼ level of detection
Note. Data from “Early diagnosis of myocardial infarction with sensitive cardiac tro
Med. 361, p. 858e67.
a 99th percentile of cTnT is 0.01 ng/mL which corresponds to 33 pg/mL of hsT0-hour, 1-hour, and 2-hour serial hsTn are adequate instead of
0 hours, 2 hours, and 6 hours to exclude an AMI. Unfortu-
nately, the diagnostic accuracy of absolute 2-hour hsTn
changes, relative 2-hour changes, and baseline hsTn levels in
differentiating unstable angina from noncardiac chest pain
were all low.
Another similar study compared high-sensitivity troponin I
(hsTnI) with conventional troponin I (cTnI)dboth manufac-
tured by AbbotteArchitectdin predicting 30 day cardiac
events (adjudicated by two independent cardiologists blinded
to hsTnI results) enrolled 1818 consecutive patients (aged
18e85 years) who presented to the chest pain unit for chest
pain or angina equivalent.16,18 Blood was drawn at admission
(0 hours), and 3 hours and 6 hours after admission to ED for
hsTnI (level of detection, LoD, 3.2 pg/mL; 10% CV, 5.2 pg/
mL; 99th percentile, 30 pg/mL), cTnI (LoD, 10 pg/mL; 10%
CV and 99th percentile, 32 pg/mL) and eight other cardiac
markers. A final diagnosis of AMI was made in 22.7% of cases
and 13.2% of patients had unstable angina. The hsTnI had the
highest AUC of 0.962 followed by cTnI (AUC, 0.921 vs.
hsTnI p < 0.001) and subsequently heart-type fatty acid
binding protein (H-FABP) (Evidence EV180 system, Randox
Laboratories Ltd., Crumlin, UK) (AUC, 0.892 vs. hsTnI
p < 0.001).
Using the LoD of hsTnI as diagnostic value, hsTnI at
0 hours achieved 100% negative predictive value (NPV) for
MI with 35% specificity. Only 26% of the study population
had hsTnI less than the LoD, and could have MI ruled out at
0 hours. Using 99th percentile as cut-off value, NPV at 0 hoursT (cTnT) levels at presentation in the diagnosis of acute myocardial infarction.
10% CV, pg/mL 99th percentile, pg/mL A p-value of comparison







ponin assays” by T. Reichlin, W. Hochholzer, S. Bassetti, et al. 2009, N Engl J
nT, 10% CV ¼ 0.03 ng/mL which corresponds to 54 pg/mL of hsTnT.
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99.4% and specificity 90.4%. However, this study showed that
the use of relative change of hsTnI at 0 hours and 3 hours did
not further improve the NPV. The addition of early marker
copetin or H-FABP only marginally increased the AUC of
hsTnI to 0.968 ( p ¼ 0.010) or 0.967 ( p ¼ 0.020), respectively,
in the diagnosis of AMI. Combining the 99th percentile cut off
at 0 hours and 3 hours, the NPV was same for hsTnI (99.4%)
as compared to when both hsTnI and cTnI were used together.
The 0-hour hsTn allows an earlier prediction of AMI than the
less sensitive cTn. Thus, the excellent performance of hsTn at
0 hours combined with a repeat reading at 2 hours or 3 hours
could negate the need for other early markers of myocardial
necrosis. Using the 99th percentile of hsTn as cutoff value to
differentiate unstable angina from noncardiac chest pain, the
AUC was 0.62 with a NPV of 84%.
At the Royal Infirmary of Edinburgh, the hospital decided
to implement hsTnI (Abbott Architect assays, Abbott
Diagnostics: LoD, 10 pg/mL, 99th percentile, 12 pg/mL; 10%
CV, 50 pg/mL) to replace the cTnI (10% CV, 200 pg/mL).19
During the validation phase, doctors would only be informed
that the troponin level was raised if plasma troponin I was
200 pg/mL. A total of 2092 patients with suspected ACS
were enrolled. Patients were followed up for a median of 453
days. Surprisingly, patients with hsTnI value of 50e190 pg/
mL were more likely to have died or had an AMI (39%) at 12
months, compared with those hsTnI < 50 pg/mL (7%) or
hsTnI  200 pg/mL (24%). However, after the implementation
phase of hsTnI, patients with hsTnI value of 50e190 pg/mL
were less likely to have died or have had an AMI at 12 months
(21%; odds ratio, 0.42; 95% CI, 0.24e0.84; p ¼ 0.01). The
results were unchanged in the hsTnI < 50 pg/mL group (5%)
and the hsTnI  200 pg/mL group (24%). Hence, adopting a
diagnostic threshold of hsTnI of 50 pg/mL increased the
number of patients diagnosed by AMI by 29%. The poorer
outcome of patients with hsTnI 50e190 pg/mL during the
validation phase may be explained by the fact that these pa-
tients did not receive treatment for AMI i.e., coronary revas-
cularization (17% vs. 59%, p < 0.01) and dual antiplatelet
therapy (27% vs. 80%, p < 0.01) due to the lack of diagnostic
information. Lowering the diagnostic threshold of TnI and
using hsTnI improved clinical outcome of those patients with
hsTnI level 50e190 pg/mL.
5. Common causes for elevated troponin levels in the
absence of ACS
In an ACS registry consisting of patients referred for early
coronary angiography or primary percutaneous intervention for
ACS, hsTn has been proven more sensitive in the diagnosis of
AMI (78% vs. 66%). However, hsTn has also been shown to
have a higher false positive rate in the diagnosis of ACS than
cTn (7% vs. 2%).20 In another prospective observation study on
337 low to intermediate risk chest discomfort patients with
clinical suspicion for ACS presenting to the ED, all patients had
a CT coronary angiography done. Conventional TnTand hsTnT
were taken just prior to the CT angiogram (median 4.2 hoursfrom presentation). Patients were followed up for 6 months.
Thirty-seven patients (10.9%) had the diagnosis of ACS (MI and
unstable angina) adjudicated by two physicians with all medical
records, including CT angiogram findings and cTnT result, but
with blinding to hsTnT. High-sensitivity TnT 13 pg/mL (99th
percentile) was more sensitive than cTnT (cut-off point 10%
CV, 0.03 ng/mL, equivalent to 53 pg/mL of hsTnT) in diag-
nosing ACS (62% vs. 35%; p¼ 0.002); however, the specificity
was significantly less than cTnT (89% vs. 99%; p < 0.001).21
Cardiac troponins are the most sensitive and specific
biochemical markers of myocardial damage. However,
troponin elevations indicate the presence but not the mecha-
nism of myocardial injury and myocardial damage can occur
from a variety of mechanisms other than acute ischemia sec-
ondary to coronary artery disease.22,23
The non-ACS causes of elevated troponin level can be
categorized as follows: (1) demand ischemia which refers to a
mismatch between myocardial oxygen demand and supply in
the absence of flow-limiting epicardial stenosis, e.g., sepsis or
septic shock, hypotension or hypovolemia, atrial fibrillation or
other tachyarrhythmias; (2) myocardial ischemia caused by
vasospasm: Prizemetal’s angina, stroke symptoms, or sub-
arachnoid hemorrhage, all of which cause damage due to an
imbalance of the automatic nervous system, with resulting
excess of sympathetic activity and increased catecholamine
effect on myocardial cells; (3) direct myocardial damage:
cardiac contusion, implantable cardioverter defibrillator
shocks, amyloidosis, cardiotoxic effects of chemotherapy,
acute pericarditis and myocarditis; (4) myocardial strain and
pressure overload of both the right and left ventricle, as in
congestive heart failure, pulmonary embolism or pulmonary
hypertension (pulmonary right-heart strain), and strenuous
exercise; and (5) chronic renal deficiency (see below).
Some of these patients can present with chest pain or
angina equivalent, such as breathlessness. It is prudent to
order and interpret the troponin test in tandem with the
clinical situation. Troponin tests should not be ordered as a
routine in patients presenting with shock and sepsis without
clinical suspicion, or those with a low pretest probability for
ACS. However, ACS patients might present with atypical
symptoms including (but are not limited to) breathlessness,
epigastric pain, backache, jaw pain, arm pain, mental
confusion, weakness, malaise, syncope, apprehension, and
nervousness. These symptoms are especially seen in elderly,
female, diabetic, and demented patients. This leads to cTn
Tests being ordered in many clinical scenarios. A slight
elevation in troponin level is common in hospitalized patients
within a large spectrum of clinical settings and comorbid-
ities. It is very important for clinicians to develop a systemic
approach to cTn elevation.
To classify troponin elevation into ACS and non-ACS is a
challenge. A diagnosis of MI requires a combination of clin-
ical history, ECG changes, troponin increase, and/or a new
wall-motion abnormality on echocardiogram or nuclear scan
showing new loss of viable myocardium. For patients with low
pretest probability of coronary artery disease, the main goal is
to identify the underlying cause of the troponin elevation.
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renal failure
High prevalence of elevated troponin levels (T more
frequently than I) are observed in patients with chronic renal
failure.24 Cardiac TnT released from injured myocardium
may have a longer circulating half-life compared with cTnI
because of advanced glycation end products known to
accumulate in diabetic patients with renal disease. Cardiac
TnI decreases after dialysis, either directly attributable to
removal by dialysis or indirectly by degradation of the labile
cTnI molecule, resulting in lower circulating cTnI levels
compared with cTnT. In a population of 733 end-stage renal
failure patients treated with intermittent hemodialysis for at
least 30 days, a substantially greater proportion of patients
had increased predialysis cTnT level relative to cTnI
(DadeeBehring, Siemens Healthcare Diagnostics) regardless
of cut-off criteria used; e.g., 99th percentile: 82% (10 pg/mL)
versus 6% (100 pg/mL); 10% CV: 53% (30 pg/mL)
versus 1.0% (400 pg/mL); and ROC: 20% (100 pg/mL)
versus 0.4% (600 pg/mL). Median patient follow-up was 1.6
patienteyears with a total of 192 deaths (26.2%). This study
reported that elevated TnT but not TnI increased the risk of
long-term mortality.
A recent study of a 143 asymptomatic dialysis patients (112
on hemodialysis and 31 on peritoneal dialysis) also suggested
that the baseline troponin cut-off values should be adjusted for
patients with renal failure.25 The patients were followed-up for
a median of 46.7 months or 3.9 years, and 55 of 143 patients
died during the course of the study (38.5%). Baseline pre-
dialysis hsTnT and TnT were measured. A cut-off point of
24.15 pg/mL for the hsTnT assay was determined using the
ROC curve analysis. cTnT assay was categorized as detected
or not detected. All individuals with hsTnT levels below
24.15 pg/mL remained alive during follow-up whereas 54 of
114 (47.4%) patients with values above this point died. This
cut-off point was more accurate in predicting prognosis than
cTnT being present or absent as was used previously. Serum
TnT levels that exceed threshold values in chronic hemodial-
ysis patients proved to be valuable for identifying patients at
risk for future adverse cardiac events.
A prospective study of 162 asymptomatic individuals
with stable chronic kidney disease not requiring renal
replacement therapy showed similar results. These patients
underwent echocardiography and coronary artery calcifica-
tion scoring.26 Blood sample collected at the time of
recruitment showed that 38% of individuals had raised hsTnI
(Dimension Vista 1500, Siemens Healthcare Diagnostics)
and 68% had raised hsTnT above the 99th percentile of the
healthy controls. During follow-up, there was found to be a
significant increase in mortality in the group of patients with
raised hsTnI and hsTnT. However, whether TnT increases
the short-term mortality (30 days) is unclear. It has also not
been well studied as to whether elevated TnT might be used
as a diagnostic tool for coronary disease and the initiation of
treatment of atherosclerotic disease in this patient
population.Cardiac disease is a major cause of death in patients with end
stage renal disease.27 However, the magnitude of rise and falls
of troponin to diagnose ACS in chronic kidney disease patients
with chest pain or angina equivalent has not been well estab-
lished. A retrospective chart review of patients with chronic
kidney disease (defined as serum creatinine> 176.8 mmol/L or
2.0 mg/L) and with suspected acute coronary syndromes pre-
senting to the ED was conducted. Changes between two
consecutive serial cTnT measurements within 12 hours showed
that in a subgroup of 64 patients with an initial cTnT mea-
surement above 100 pg/mL, an increase in cTnT of 110 pg/mL
in a second cTnT measurement within 12 hours had a positive
likelihood ratio of 13.3 and 11.9 for in-hospital and 30-day
adverse cardiac event, respectively.28
7. Detectable hsTn level in the community
Cardiac hsTnT was detectable (3 pg/mL) in 80.9% of a
healthy population, e.g., workers of a company aged 35e63
years, excluding those with cardiovascular disease (CVD) and
on hemodialysis.29 2.2% of this population had hsTnT level of
more than 10 pg/mL. The odds ratio for a high predicted CVD
risk (10 year risk, 20%) in the highest tertile of hsTnT
(5 pg/mL) in comparison to the lowest tertile (2 pg/mL)
was 3.98 (95% CI 1.72e9.24; p ¼ 0.001). No participants had
a detectable troponin when measured by the cTn (10% CV,
30 pg/mL, corresponding to 53 pg/mL of hsTnT). Similarly,
cardiac hsTnT was detectable in 66.2% of a community pop-
ulation (n ¼ 4421) aged 65 years or older without prior heart
failure and 16.6 % of this population had hsTnT more than the
99th percentile (13 pg/mL).30 Again, the population with
hsTnT  13 pg/mL was associated with an increased inci-
dence rate of cardiovascular death compared to those with
undetectable hsTnT (4.8%; 95% CI, 4.3e5.4 vs. 1.6%; 95%
CI, 1.4e1.8). These findings may suggest the usefulness of
measuring hsTnT to identify high-risk individuals in the pri-
mary prevention of CVD. This may also explain why hsTn has
a higher false positive rate in the diagnosis of AMI than cTn. It
is unclear at present whether we should use a higher cut-off
value for making the diagnosis of AMI in chest pain patients
aged  65 years.
8. Diagnosis of unstable angina
In our ED population, about 5e10% of patients with chest
pain, nondiagnostic ECGs, and low level of serial hsTn (<99th
percentile) could still have unstable angina, i.e., underlying
severe coronary artery disease. Thus, the identification of pa-
tients with unstable angina remains a real challenge. Currently,
we have to rely on expensive and labor-intensive cardiac in-
vestigations such as stress ECG, stress nuclear scan, or CT
coronary angiogram.31,32 By contrast, elevated B-type natri-
uretic peptide levels in the presence of acute coronary syndrome
predict a worse outcome, but B-type natriuretic peptide has not
been shown to be a good marker for the diagnosis of acute
coronary syndrome or unstable angina.33 Currently, new cardiac
markers such as ischemic-modified albumin, copeptin, and free
130 S.H. Lim, Z. Lin / Journal of Acute Medicine 3 (2013) 125e131fatty acid binding protein34e36 have shown potential in diag-
nosing ACS, and are still being extensively studied, with the
hopes that one of them may have utility in the diagnosis of
unstable angina.
9. Conclusion
In the context of patients presenting to the ED with chest
discomfort, hsTn has been proven to be more sensitive than cTn
in the diagnosis of AMI, especially in those with small AMI,
and in patients who present early to the ED. Cardiac hsTn has
provided strong diagnostic information even in cTn-negative
patients, and the excellent performance of hsTn at 0 hours
combined with 2 hours or 3 hours could negate the need for
other early markers of myocardial necrosis. More studies
should be done as to whether this combination is adequate, or if
6-hour hsTn will increase the sensitivity in the diagnosis of
AMI.
However, hsTn has also been shown to have a higher false
positive rate in the diagnosis of ACS than cTn. It is therefore
important to appreciate the non-ACS causes of elevated tro-
ponins, both cardiac and noncardiac, in its interpretation.
Troponin tests should thus not be ordered routinely in patients
with clinical presentations that are not consistent with ACS
and in whom the pretest probability for a cardiac event is low.
Given its pitfalls, it would be inappropriate to over-
emphasize the importance of troponins. Cardiac markers are
but an isolated portion of a picture: a diagnosis of MI requires
a combination of clinical history, ECG changes, new wall-
motion abnormality on echocardiogram or nuclear scan
showing new loss of viable myocardium, in addition to
changes in cTn levels. Moreover, good clinical skill is still
required to differentiate illnesses that mimic ACS and also
cause elevated troponin, such as pulmonary embolism.
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